Marco D'amelio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3438571/publications.pdf

Version: 2024-02-01

88 papers

3,649 citations

33 h-index 57 g-index

92 all docs 92 docs citations 92 times ranked 5238 citing authors

#	Article	IF	CITATIONS
1	Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health, The, 2022, 7, e74-e85.	10.0	156
2	Vitamin D and Parkinson's Disease. Nutrients, 2022, 14, 1220.	4.1	32
3	Analysis of the LRP10 gene in patients with Parkinson's disease and dementia with Lewy bodies from Southern Italy. Neurological Sciences, 2021, 42, 305-308.	1.9	5
4	Transcranial magnetic resonance-guided focused ultrasound thalamotomy as a safe treatment option in multiple sclerosis patients with essential tremor. Neurological Sciences, 2021, 42, 1139-1143.	1.9	5
5	Lowering the recommended age for the free and active offer of influenza vaccination in Italy: clinical and economic impact analysis in the Liguria region. Human Vaccines and Immunotherapeutics, 2021, 17, 1387-1395.	3.3	3
6	Stroke incidence and case fatality: a 9-year prospective population-based study in an elderly population of Bagheria, Italy. Neurological Sciences, 2021, 42, 2447-2452.	1.9	4
7	A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. Journal of Parkinson's Disease, 2021, 11, 187-198.	2.8	31
8	Transcranial Magnetic Resonance Imaging-Guided Focused Ultrasound with a 1.5 Tesla Scanner: A Prospective Intraindividual Comparison Study of Intraoperative Imaging. Brain Sciences, 2021, 11, 46.	2.3	2
9	The state of stroke services across the globe: Report of World Stroke Organization–World Health Organization surveys. International Journal of Stroke, 2021, 16, 889-901.	5 . 9	68
10	Preoperative imaging findings in patients undergoing transcranial magnetic resonance imaging-guided focused ultrasound thalamotomy. Scientific Reports, 2021, 11, 2524.	3.3	2
11	Case series: Multiple sclerosis clinical onset and relapse after SARS-CoV-2 Infection. Journal of the Neurological Sciences, 2021, 429, 118152.	0.6	O
12	Autonomic symptoms in motor subtypes of Parkinson's disease. Journal of the Neurological Sciences, 2021, 429, 117836.	0.6	0
13	Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection. Neurology International, 2021, 13, 695-700.	2.8	18
14	Assessment of the Kinematic Adaptations in Parkinson's Disease Using the Gait Profile Score: Influences of Trunk Posture, a Pilot Study. Brain Sciences, 2021, 11, 1605.	2.3	3
15	Cognitive and motor effects of Kinectâ€based games training in people with and without Parkinson disease: A preliminary study. Physiotherapy Research International, 2020, 25, e1807.	1.5	17
16	Transcranial Magnetic Resonance Imaging-Guided Focused Ultrasound Treatment at 1.5 T: A Retrospective Study on Treatment- and Patient-Related Parameters Obtained From 52 Procedures. Frontiers in Physics, 2020, 7, .	2.1	9
17	Impaired circadian heart rate variability in Parkinson's disease: a time-domain analysis in ambulatory setting. BMC Neurology, 2020, 20, 152.	1.8	16
18	Intraoperative imaging findings in transcranial MR imaging-guided focused ultrasound treatment at 1.5T may accurately detect typical lesional findings correlated with sonication parameters. European Radiology, 2020, 30, 5059-5070.	4. 5	14

#	Article	IF	Citations
19	DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB. Neurobiology of Aging, 2020, 93, 143.e5-143.e7.	3.1	3
20	Effects of transcranial random noise stimulation combined with Graded Repetitive Arm Supplementary Program (GRASP) on motor rehabilitation of the upper limb in sub-acute ischemic stroke patients: a randomized pilot study. Journal of Neural Transmission, 2019, 126, 1701-1706.	2.8	18
21	The Mystery of "Red Ear Syndrome― Sign or Syndrome. Headache, 2019, 59, 624-625.	3.9	O
22	Preliminary experience with a transcranial magnetic resonance–guided focused ultrasound surgery system integrated with a 1.5-T MRI unit in a series of patients with essential tremor and Parkinson's disease. Neurosurgical Focus, 2018, 44, E7.	2.3	45
23	Urological dysfunctions in patients with Parkinson's disease: clues from clinical and non-invasive urological assessment. BMC Neurology, 2018, 18, 148.	1.8	7
24	Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study. BMC Neurology, 2017, 17, 155.	1.8	40
25	Effects of More-Affected vs. Less-Affected Motor Cortex tDCS in Parkinson's Disease. Frontiers in Human Neuroscience, 2017, 11, 309.	2.0	32
26	Factors influencing psychological well-being in patients with Parkinson's disease. PLoS ONE, 2017, 12, e0189682.	2.5	32
27	Frequency and determinants for hemorrhagic transformation of posterior cerebral stroke. BMC Research Notes, 2017, 10, 592.	1.4	17
28	Red Ear Syndrome. Current Pain and Headache Reports, 2016, 20, 19.	2.9	23
29	Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease. Neurological Sciences, 2015, 36, 2305-2305.	1.9	6
30	Juvenile Migraine and Allodynia: Results of a Retrospective Study. Headache, 2015, 55, 413-418.	3.9	14
31	Migraine and Cranial Autonomic Symptoms in Children and Adolescents. Journal of Child Neurology, 2015, 30, 182-186.	1.4	24
32	In patient's with Parkinson disease, autonomic symptoms are frequent and associated with other non-motor symptoms. Clinical Autonomic Research, 2015, 25, 301-307.	2.5	32
33	Migraine in a pediatric population: a clinical study in children younger than 7Âyears of age. Developmental Medicine and Child Neurology, 2015, 57, 585-588.	2.1	22
34	Transcranial direct current stimulation for treatment of freezing of gait: A crossâ€over study. Movement Disorders, 2014, 29, 1064-1069.	3.9	103
35	Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study. Neurological Sciences, 2014, 35, 1173-1180.	1.9	80
36	Insidious onset of Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease. Neurological Sciences, 2014, 35, 1615-1617.	1.9	6

#	Article	IF	Citations
37	Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology, 2014, 83, 215-220.	1.1	98
38	Early and Late Mortality of Spontaneous Hemorrhagic Transformation of Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 649-654.	1.6	42
39	Sleep quality in caregivers of patients with Alzheimer's disease and Parkinson's disease and its relationship to quality of life – CORRIGENDUM. International Psychogeriatrics, 2013, 25, 1211-1211.	1.0	1
40	Incidence of amyotrophic lateral sclerosis in Sicily: A population based study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 284-287.	2.1	40
41	Tumor Diagnosis Preceding Alzheimer's Disease Onset: Is There a Link Between Cancer and Alzheimer's Disease?. Journal of Alzheimer's Disease, 2012, 31, 177-182.	2.6	45
42	Sleep quality in caregivers of patients with Alzheimer's disease and Parkinson's disease and its relationship to quality of life. International Psychogeriatrics, 2012, 24, 1827-1835.	1.0	64
43	Dentatorubral-pallidoluysian atrophy: Haplotype of Asian origin in 2 Italian families. Movement Disorders, 2012, 27, 460-461.	3.9	4
44	Protective Role of Heat Shock Proteins in Parkinson's Disease. Neurodegenerative Diseases, 2011, 8, 155-168.	1.4	66
45	MRI abnormalities following repeated and incoming seizures. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 90-92.	2.0	6
46	Answer to: The possible risk of cancer in multiple sclerosis patients: a controversial issue. European Journal of Neurology, 2011, 18, e50-e50.	3.3	2
47	Reversible posterior leukoencephalopathy syndrome in a patient with thrombotic thrombocytopenic purpura. Neurological Sciences, 2011, 32, 469-472.	1.9	6
48	Prevalence of red ear syndrome in juvenile primary headaches. Cephalalgia, 2011, 31, 597-602.	3.9	27
49	A Population-Based Survey of Cognitive Performance in a Sicilian Elderly Community. Neuroepidemiology, 2011, 36, 169-176.	2.3	6
50	Cholesterol Levels and Risk of Hemorrhagic Transformation after Acute Ischemic Stroke. Cerebrovascular Diseases, 2011, 32, 234-238.	1.7	42
51	Leprosy: report of a case with severe peripheral neuropathy. Neurological Sciences, 2010, 31, 75-77.	1.9	12
52	Multiple sclerosis survival: a populationâ€based study in Sicily. European Journal of Neurology, 2010, 17, 391-397.	3.3	31
53	Frequency and Determinants for Hemorrhagic Transformation of Cerebral Infarction. Neuroepidemiology, 2009, 33, 261-265.	2.3	96
54	Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study. Multiple Sclerosis Journal, 2009, 15, 204-211.	3.0	16

#	Article	IF	Citations
55	Realâ€life impact of early interferonî² therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520.	5. 3	132
56	Predictors of caregiver burden in partners of patients with Parkinson's disease. Neurological Sciences, 2009, 30, 171-174.	1.9	74
57	Blood levels of homocysteine, cysteine, glutathione, folic acid, and vitamin B12 in the acute phase of atherothrombotic stroke. Neurological Sciences, 2009, 30, 361-364.	1.9	54
58	Progressive necrotic encephalopathy following tacrolimus therapy for liver transplantation. Neurological Sciences, 2009, 30, 527-529.	1.9	7
59	Parkinson's Disease and Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 324-334.	3.8	35
60	Diabetes preceding Parkinson's disease onset. A case–control study. Parkinsonism and Related Disorders, 2009, 15, 660-664.	2.2	74
61	Motor intracortical inhibition in PD: L-DOPA modulation of high-frequency rTMS effects. Experimental Brain Research, 2008, 184, 521-528.	1.5	41
62	Myocardial ¹²³ metaiodobenzylguanidine uptake in genetic Parkinson's disease. Movement Disorders, 2008, 23, 21-27.	3.9	61
63	Mortality in multiple sclerosis: a review. European Journal of Neurology, 2008, 15, 123-127.	3.3	82
64	Body mass index does not change before Parkinson's disease onset. European Journal of Neurology, 2008, 15, 965-968.	3.3	30
65	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism and Related Disorders, 2008, 14, 266-267.	2.2	0
66	Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 509-512.	2.2	8
67	Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily. Parkinsonism and Related Disorders, 2008, 14, 572-575.	2.2	13
68	High Prevalence and Fast Rising Incidence of Multiple Sclerosis in Caltanissetta, Sicily, Southern Italy. Neuroepidemiology, 2007, 28, 28-32.	2.3	45
69	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism and Related Disorders, 2007, 13, 528-531.	2.2	77
70	Height as a potential indicator of early life events predicting Parkinson's disease: A caseâ€control study. Movement Disorders, 2007, 22, 2263-2267.	3.9	10
71	Dropped head as an unusual presenting sign of myasthenia gravis. Neurological Sciences, 2007, 28, 104-106.	1.9	25
72	Search for Genetic Factors Associated with Susceptibility to Multiple Sclerosis. Annals of the New York Academy of Sciences, 2006, 1067, 264-269.	3.8	20

#	Article	IF	CITATIONS
73	Implications for Estrogens in Parkinson's Disease: An Epidemiological Approach. Annals of the New York Academy of Sciences, 2006, 1089, 373-382.	3.8	55
74	Long–term survival of Parkinson's disease. Journal of Neurology, 2006, 253, 33-37.	3.6	133
75	Age at menopause predicts age at onset of Parkinson's disease. Movement Disorders, 2006, 21, 2211-2214.	3.9	48
76	Mortality in the First 30 Days Following Incident Acute Symptomatic Seizures. Epilepsia, 2005, 46, 43-45.	5.1	32
77	DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex. Annals of Neurology, 2005, 58, 803-807.	5.3	169
78	Levetiracetam in the treatment of vascular chorea: a case report. European Journal of Clinical Pharmacology, 2005, 60, 835-836.	1.9	23
79	Prevalence and risk factors of post-polio syndrome in a cohort of polio survivors. Journal of the Neurological Sciences, 2005, 236, 31-35.	0.6	49
80	Risk of Parkinson disease in women. Neurology, 2004, 62, 2010-2014.	1.1	147
81	Multiple Sclerosis in Southern Europe: Monreale City, Italy. Neuroepidemiology, 2004, 23, 306-309.	2.3	26
82	The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurologica Scandinavica, 2004, 110, 23-26.	2.1	71
83	Tumor diagnosis preceding Parkinson's disease: A case-control study. Movement Disorders, 2004, 19, 807-811.	3.9	30
84	Incidence and risk factors in sudden unexpected death in epilepsy. Neurology, 2001, 56, 519-525.	1.1	473
85	Transient topographical amnesia and cingulate cortex damage: A case report. Neuropsychologia, 1996, 34, 321-326.	1.6	73
86	The IHS Classification Criteria for Migraine Headaches in Adolescents Need Minor Modifications. Headache, 1996, 36, 362-366.	3.9	34
87	Monosymptomatic presentation of type I Arnold-Chiari malformation: Report of two cases. Italian Journal of Neurological Sciences, 1994, 15, 55-60.	0.1	2
88	Influence of ventral tegmental area (A10 region) on flight behaviour elicited by hypothalamic stimulation in the cat. Brain Research, 1993, 610, 242-247.	2.2	3